2025-06-11-Jefferies-哈门那（HUM）_Humana公司I日预览_管理层对星级和每股收益（EPS）的信心如何_13页_368kb

HUM I-Day Preview Summary

Core Content and Key Points

This document provides an analysis of Humana's (HUM) stock performance and earnings outlook, focusing on the impact of the Stars ratings and EPS (Earnings Per Share) projections for the upcoming fiscal years. The analysis is centered around three key scenarios: base case, upside, and downside, and evaluates how different factors could influence the stock price and EPS performance.

Main Viewpoints

1. Stars Lawsuit Impact

• A potential win in the Stars lawsuit could result in a one-time positive stock move of approximately +MSD%.
• The estimated value of the lawsuit is ~$2.6B, which could translate to a one-time EPS benefit of ~$16.
• However, the majority of the impact is already priced in, so the upside is limited.
• Investors are likely to view the win as a one-time benefit, not a long-term catalyst.

2. Stars Performance in PY26/BY27

• HUM's Stars performance in the next cycle is largely independent of the current lawsuit outcome.
• Approximately 70%+ of HUM's MA membership is on the 4-star threshold, meaning small performance changes could affect ratings.
• The company must overcome a headwind from reweightings, with a potential moderate impact of 0.1-0.2 raw score.
• The Stars rating methodology is changing, with claims-based/HEDIS measures increasing in weighting from 30% to 53%.
• This shift could reduce raw scores for HUM's largest plans, especially H5216, which has ~47% of total MA membership.

3. EPS and Stock Price Projections

• The current stock price is ~$231.98, with a price target of $244 (+5%).
• In the base case, 2027E EPS is estimated at $20.65, with a 12x multiple, resulting in a price target of $248.
• In the upside scenario, where Stars appeals are successful, 2027E EPS is projected at $35.35, with a 10x multiple, leading to a price target of $353.
• In the downside scenario, where appeals fail and no members are recaptured, 2027E EPS is expected to be $14.46, with a 12x multiple, leading to a price target of $158.

Key Information

4. MA Margin and Repricing

• HUM's MA book is currently at ~0% margin in PY25, with a target of 3%.
• The company must improve margins by ~500 bps through repricing, which is challenging due to:
  • The need for effective Stars investments.
  • The limited number of profitable plans to exit.
  • Potential repricing of Group MA contracts, which could lead to member premium increases.
• Benefit reductions are a potential option but must be managed carefully to avoid significant membership loss.

5. RAF Regulation Impact

• Possible approaches to RAF regulation include disallowing HRAs and CRs or targeting "codes without care."
• These measures are expected to be an absolute headwind for HUM, but on a relative basis, the impact is similar or slightly better than the industry average.
• HUM is likely to have already priced in most of the impact.

6. Investor Day and Earnings Outlook

• The 2Q25 earnings and PY25 Stars appeal ruling are important catalysts.
• The document includes detailed EPS bridges for 2024-2027, showing the impact of various factors like Stars performance, MLR improvements, and benefit reductions.

7. ESG and Sustainability

• HUM has set targets to reduce GHG emissions by 54.6% by 2032 (from 2019).
• The document raises questions about HUM's plans to expand ESG initiatives to human capital and healthcare access.
• The ownership of Centerwell Primary Care is highlighted as a potential advantage in improving access, quality, and affordability for seniors.

Investment Thesis and Key Differences

• HUM is expected to benefit from its scale and competencies in MA, especially as industry MA growth is likely to be stunted during the V28 implementation period.
• The Centerwell business is seen as a driver of top-line and EBIT growth.
• The company is under pressure to improve margins through repricing and benefit reductions, but faces challenges due to the current MA margin situation.

Summary Table of Key Metrics

Catalysts and Determining Factors

• Investor Day (June 16th): Expected to provide insights into HUM's strategy and financial outlook.
• 2Q25 Earnings: Will offer updated performance metrics and guidance.
• PY25 Stars Appeal Ruling: A critical event that could influence future ratings and EPS.
• MA Margin Impact from Utilization: Could affect the company's ability to improve margins.
• MA Enrollment Read-outs for PY25: Important for assessing growth and performance.
• Legislation and Regulatory Announcements: Around risk-coding and prior authorization could impact operations.

Final Notes

• The analysis emphasizes the importance of Stars performance in HUM's EPS recovery.
• The company faces challenges in improving margins due to the current MA margin situation and potential repricing pressures.
• The document suggests that HUM's ability to reinvest windfalls from Stars lawsuits and manage its ESG initiatives will be key to long-term success.